Biohaven provides update on phase 2/3 trial and alzheimer's disease program

New haven, conn., jan. 18, 2021 /prnewswire/ -- biohaven pharmaceutical holding company ltd. (nyse: bhvn) today announced that it has completed a focused analysis of the topline co-primary and key secondary data from its phase 2/3 clinical trial of troriluzole as a symptomatic treatment...

BHVN Ratings Summary

BHVN Quant Ranking